US RE50,617 E1
Method for stress management and overall health status improvement and compositions used therein
Jayant Deshpande, Congers, NY (US); James M Stringham, Durham, NC (US); and Vijaya Juturu, Morristown, NJ (US)
Filed by OMNIACTIVE HEALTH TECHNOLOGIES LIMITED, Maharashtra (IN)
Filed on Mar. 7, 2022, as Appl. No. 17/687,712.
Application 17/687,712 is a reissue of application No. 15/058,821, filed on Mar. 2, 2016, granted, now 10,583,095, issued on Mar. 10, 2020.
Claims priority of provisional application 62/126,971, filed on Mar. 2, 2015.
Int. Cl. A61K 31/047 (2006.01); A61K 31/07 (2006.01); A61P 25/00 (2006.01); A61P 27/00 (2006.01); G01N 21/59 (2006.01); G01N 30/00 (2006.01); G01N 30/88 (2006.01); G01N 33/487 (2006.01); G01N 33/74 (2006.01)
CPC A61K 31/047 (2013.01) [A61K 31/07 (2013.01); A61P 25/00 (2018.01); A61P 27/00 (2018.01); G01N 21/5907 (2013.01); G01N 30/00 (2013.01); G01N 33/487 (2013.01); G01N 33/743 (2013.01); G01N 30/88 (2013.01); G01N 2030/8813 (2013.01); G01N 2800/52 (2013.01)] 18 Claims
 
1. A method for treatment of [ improving, managing, and/or treating ] psychological stress and [ and/or ] physiological stress in a subject, comprising:
a . [ ) ] identifying a subject in need thereof, wherein the subject in need thereof is affected by psychological stress as measured by macular pigment optical density (MPOD) levels and [ and/or ] physiological stress as measured by blood cortisol levels;
b . [ ) ] administering a daily dose of macular carotenoid composition in an amount effective for increasing the MPOD levels and reducing the blood cortisol levels over a period of at least one month as compared to those of before the administration of the macular carotenoid composition so as to treat stress in the subject, the macular carotenoid composition consists [ consisting ] of at least 85% by weight of xanthophylls, the xanthophylls being lutein and zeaxanthin isomers, of which at least 80% by weight being trans-lutein, at least 6% by weight being (R, R)-zeaxanthin and at least 6% by weight being (R, S)-zeaxanthin, wherein the macular carotenoid composition consists of at least 0.1 mg/kg body weight of the lutein and, at least 0.01 mg/kg body weight of the zeaxanthin isomers; and
c . [ ) ] measuring MPOD and [ and/or ] blood cortisol levels; and
d . [ ) ] evaluating an improvement in overall health status of the subject.